Sun Pharma to acquire US based eyesore firm Insite Vision
Q. Which drug pharma major has entered into an agreement to acquire US based eyesore firm Insite Vision for USD 48 million plus related debt and transaction costs:- Published on 17 Sep 15a. Ranbaxy
b. Sun Pharma
c. Abbott
d. None of the above
ANSWER: Sun Pharma
This move will strengthen Sun’s branded ophthalmic portfolio in the US. The deal gives Sun Pharma access to four late stage branded ophthalmic products in the US. For the 6-month period ending June, InSite Vision recorded revenues of $3.8 million, an EBITDA loss of USD 6.4 million and a net loss of $7.5 million.
